Welcome to our dedicated page for Medpace Holdings news (Ticker: MEDP), a resource for investors and traders seeking the latest updates and insights on Medpace Holdings stock.
Medpace Holdings, Inc. reports developments in its global, full-service clinical contract research organization business, providing Phase I-IV clinical development services to biotechnology, pharmaceutical and medical device companies. Company news centers on quarterly and annual operating results, conference-call announcements and performance measures used in the CRO model, including revenue, EBITDA, backlog conversion, net new business awards and book-to-bill ratios.
Updates also describe Medpace's therapeutic and regulatory expertise across major development areas such as oncology, cardiology, metabolic disease, endocrinology, central nervous system, and anti-viral and anti-infective programs.
Medpace Holdings, Inc. (Nasdaq: MEDP) announced a 6.5% increase in third quarter 2020 revenue to $230.4 million compared to $216.2 million in 2019. The net book-to-bill ratio stood at 1.37x with net new business awards of $315.4 million. GAAP net income reached $41.5 million ($1.09 per diluted share), representing an 18.0% net income margin. EBITDA surged by 49.4% to $51.9 million. The company forecasts 2020 revenue between $880 million and $920 million and expects 2021 revenue to range from $1.050 billion to $1.125 billion.